KLOW (Blend)

What Is KLOW? KPV, GHK-Cu, BPC-157 and TB-500

UKPWritten and published by UK Peptides2 min readUpdated 5 cited sources

The short answer

KLOW is a co-lyophilised research blend of four peptides in one vial: KPV at 342.43 Da, GHK-Cu at 402.92 Da, BPC-157 at 1419.5 Da and TB-500 (full-length thymosin beta-4) at 4,963 Da, totalling 80mg. It is GLOW's three components plus KPV.

Key facts

Components
Four
KPV
342.43 Da, CID 125672
GHK-Cu
402.92 Da, CID 71587328
TB-500 (thymosin beta-4)
4,963 Da, CID 16132341
BPC-157
1419.5 Da, CID 9941957
Total mass
80 mg
Size range
342.43 to 4,963 Da, over fourteenfold
Relationship to GLOW
Same three plus KPV

What it is

The KLOW peptide blend is four peptides freeze-dried together in one vial. Three of them, GHK-Cu, BPC-157 and TB-500, make up the GLOW stack. KLOW adds KPV, the C-terminal tripeptide of alpha-melanocyte-stimulating hormone, and raises the total from 70mg to 80mg.

What KPV brings

A different literature. The other three sit in collagen, repair and cell migration research; KPV's published work is anti-inflammatory, including murine colitis models and a targeted delivery study. Adding it widens the blend's research coverage rather than reinforcing what was already there.

Research material referenced

KLOW 80mg, third-party HPLC tested

Buy KLOW · £79.99

The size range this creates

342.43 Da to 4,963 Da, a span of more than fourteenfold, the widest of any product in this catalogue. Four molecules of very different size, charge and solubility in one co-lyophilised cake. That has practical consequences for how the material dissolves and for what a single set of storage conditions has to accommodate.

An unremarked family connection

KPV descends from alpha-MSH. So does MT-2, which sits in a completely separate product category here, and the two take opposite halves of that hormone, KPV the anti-inflammatory C-terminus and MT-2 the receptor-binding core. Nothing in either product listing indicates they are related at all.

The figure that is still absent

80mg is a total across four components, and the split is not stated. With four components rather than three there are more unknowns, not fewer, and the same limitation applies with more force: no per-component molar calculation is possible.

Regulatory position

None of the four components holds a marketing authorisation from the MHRA, EMA or FDA, and neither does the blend. It is supplied for laboratory research only.

Frequently asked questions

What is in KLOW?

KPV at 342.43 Da, GHK-Cu at 402.92 Da, BPC-157 at 1419.5 Da and TB-500 (full-length thymosin beta-4) at 4,963 Da, totalling 80mg.

How does it differ from GLOW?

It is the same three components plus KPV, at 80mg rather than 70mg.

Is the per-component split stated?

No. With four components there are more unknowns than in a three-component blend, not fewer.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More KLOW (Blend) articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.